Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transoma launches $75m IPO:

This article was originally published in Clinica

Executive Summary

Implantable wireless diagnostics specialist Transoma Medical is aiming to raise $75m through flotation on the Nasdaq Stock Exchange. The St Paul, Minnesota-based firm aims to channel the proceeds from the IPO towards development of its technology for monitoring chronic cardiovascular disease (CVD) and its Sleuth implantable ECG monitoring system for patient management. Transoma is targeting the CVD market and is hoping to use some of the proceeds on acquisitions of businesses, technologies and products. According to Transoma, CVD has a total annual treatment cost of $280bn in the US. The company will list under the ticker symbol "TSMA".

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049972

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel